Latest Market Entry News

AML3D Limited surged to a record $12.5 million revenue in FY26, delivering its first half-year EBITDA profit and locking in a $29 million order book driven by US Defence contracts and UK market entry.

X2M Connect Limited lifted revenue by 38% to $8.94 million in FY26, halving its net loss while laying groundwork for a new data centre business.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

Articore Group Limited (ASX:ATG) has swung to a $10.3 million EBIT profit in FY26, marking its first full-year profit since listing outside the pandemic spike, driven by margin gains and strategic acquisitions including India-based Frankly Wearing.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Swift TV Ltd advanced its commercial rollout with 7,190 devices sold and secured key technology certifications in FY26, while navigating a 22% revenue decline due to legacy contract wind-downs. The company delivered positive EBITDA and raised $2.3 million to fund growth initiatives.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.